Last month Enzon planned to acquire the North American and Japanese rights to the antifungal, Abelcet, from Elan with a total payment of US$370 M. This feature presents an overview of the market for systemic antifungal drugs and examines the benefits and drawbacks in the acquisition of Abelcet from Elan.